3-(5-methoxy-3,4-dihydronaphthalen-1-yl)propanoic acid | 439803-30-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 3-(5-methoxy-3,4-dihydronaphthalen-1-yl)propanoic acid
• CAS: 439803-30-2
• 化学式: C₁₄H₁₆O₃
• 分子量: 232.279
• InChiKey: GXDACNPERJSGOF-UHFFFAOYSA-N

物化性质

• 沸点：
  417.0±45.0 °C(Predicted)
• 密度：
  1.159±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(5-methoxy-3,4-dihydronaphthalen-1-yl)propanoic acid 在 吡啶盐酸盐 作用下， 反应 3.0h， 生成 3-(5-hydroxy-3,4-dihydronaphthalen-1-yl)propanoic acid
  参考文献：
  名称：

  DIHYDRONAPHTHALENE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT

  摘要：

  公开号：

  EP1354879B1
• 作为产物：
  描述：

  5-甲氧基-3,4-二氢-2H-1-萘酮 、 丁二酸二乙酯 在 potassium tert-butylate 、 盐酸 、 溶剂黄146 作用下， 以 叔丁醇 为溶剂， 生成 3-(5-methoxy-3,4-dihydronaphthalen-1-yl)propanoic acid
  参考文献：
  名称：

  Discovery of new diphenyloxazole derivatives containing a pyrrolidine ring: Orally active prostacyclin mimetics. Part 2

  摘要：

  Synthetic and biological evaluation of novel diphenyloxazole derivatives containing a pyrrolidine ring, as a prostacyclin mimetic without the PG skeleton, are described. Asymmetric reduction of a ketone using a chiral Ru complex and reductive amination by NaBH4 produces four isomers of the tetrahydronaphthalene ring and the pyrrolidine ring with high stereoselectivity. FR193262 (4), (R,R)-diphenyloxazolyl pyrrolidine derivative, displays high potency and agonist efficacy at the IP receptor and has good bioavailability in rats and dogs. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.04.042

文献信息

• Dihydronaphthalene derivative compounds and drugs containing these compounds as the active ingredient
  申请人：——

  公开号：US20040138213A1

  公开（公告）日：2004-07-15

  A compound of formula (I) 1 (wherein all symbols are as defined in the specification) and salt thereof, and peroxisome proliferator activated receptor regulator comprising thereof as active ingredient. Because a compound of formula (I) have an activity of regulating peroxisome proliferator activated receptor regulator, the compound of formula (I) is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive and/or treatment agent for diseases associating metabolic disorders (diabetes, obesity, syndrome X, hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipemia, atherosclerosis, hypertension, circulatory diseases, overeating, coronary heart diseases, etc., an HDL cholesterol-elevating agent, an LDL cholesterol and/or VLDL cholesterol-lowering agent and a drug for relief from risk factors of diabetes or syndrome X.

  化合物式为（I）1（其中所有符号如规范所定义）及其盐，以及包含其作为活性成分的过氧化物酶增殖物激活受体调节剂。由于化合物（I）具有调节过氧化物酶增殖物激活受体调节剂的活性，因此化合物（I）可用作降糖剂、降脂剂、预防和/或治疗代谢紊乱相关疾病（糖尿病、肥胖症、X综合征、高胆固醇血症、高脂蛋白血症等）、高脂血症、动脉粥样硬化、高血压、循环系统疾病、暴饮暴食、冠心病等，是一种升高HDL胆固醇的药物，降低LDL胆固醇和/或VLDL胆固醇的药物，并可缓解糖尿病或X综合征的风险因素。
• Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient
  申请人：Tajima Hisao

  公开号：US20060287304A1

  公开（公告）日：2006-12-21

  A compound of formula (I) (wherein all symbols are as defined in the specification) and salt thereof, and peroxisome proliferator activated receptor regulator comprising thereof as active ingredient. Because a compound of formula (I) have an activity of regulating peroxisome proliferator activated receptor regulator, the compound of formula (I) is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive and/or treatment agent for diseases associating metabolic disorders (diabetes, obesity, syndrome X, hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipemia, atherosclerosis, hypertension, circulatory diseases, overeating, coronary heart diseases, etc., an HDL cholesterol-elevating agent, an LDL cholesterol and/or VLDL cholesterol-lowering agent and a drug for relief from risk factors of diabetes or syndrome X.

  化合物公式（I）（其中所有符号如规范中定义）及其盐，以及包含其作为活性成分的过氧化物酶增殖物激活受体调节剂。由于化合物公式（I）具有调节过氧化物酶增殖物激活受体调节剂的活性，因此化合物公式（I）可用作降血糖剂、降血脂剂、预防和/或治疗代谢紊乱疾病（糖尿病、肥胖症、X综合征、高胆固醇血症、高脂蛋白血症等）、高脂血症、动脉硬化、高血压、循环系统疾病、暴饮暴食、冠心病等，以及升高高密度脂蛋白胆固醇的药物、降低低密度脂蛋白和/或极低密度脂蛋白胆固醇的药物以及缓解糖尿病或X综合征风险因素的药物。
• US7220864B2
  申请人：——

  公开号：US7220864B2

  公开（公告）日：2007-05-22
• Discovery of new diphenyloxazole derivatives containing a pyrrolidine ring: Orally active prostacyclin mimetics. Part 2
  作者：Kouji Hattori、Osamu Okitsu、Seiichiro Tabuchi、Kiyoshi Taniguchi、Mie Nishio、Satoshi Koyama、Jiro Seki、Kazuo Sakane

  DOI：10.1016/j.bmcl.2005.04.042

  日期：2005.7

  Synthetic and biological evaluation of novel diphenyloxazole derivatives containing a pyrrolidine ring, as a prostacyclin mimetic without the PG skeleton, are described. Asymmetric reduction of a ketone using a chiral Ru complex and reductive amination by NaBH4 produces four isomers of the tetrahydronaphthalene ring and the pyrrolidine ring with high stereoselectivity. FR193262 (4), (R,R)-diphenyloxazolyl pyrrolidine derivative, displays high potency and agonist efficacy at the IP receptor and has good bioavailability in rats and dogs. (c) 2005 Elsevier Ltd. All rights reserved.
• DIHYDRONAPHTHALENE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1354879B1

  公开（公告）日：2007-08-15